Used in the treatment of geographic atrophy (GA), a late form of age-related macular degeneration (AMD), this antibody targets complement factor D, a key enzyme in the alternative complement pathway. By inhibiting factor D, it reduces chronic inflammation and prevents uncontrolled activation of the complement system in the retina. This helps slow the progression of retinal damage and vision loss in patients with GA. Administered via intravitreal injection, it represents a targeted therapy aimed at modifying the disease course rather than just managing symptoms.